Citation Impact
Citing Papers
Intracellular Tumor-Associated Antigens Represent Effective Targets for Passive Immunotherapy
2012 StandoutNobel
Systemic CTLA-4 Blockade Ameliorates Glioma-Induced Changes to the CD4+ T Cell Compartment without Affecting Regulatory T-Cell Function
2007 StandoutNobel
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
2007 Standout
Systemic Targeting of CpG-ODN to the Tumor Microenvironment with Anti–neu-CpG Hybrid Molecule and T Regulatory Cell Depletion Induces Memory Responses in BALB-neuT Tolerant Mice
2008 StandoutNobel
HER2/neu expression in adenoid cystic carcinoma of salivary gland origin: an immunohistochemical study
2002
Single‐institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting
2010 StandoutNobel
Epithelial-mesenchymal transition and its implications for fibrosis
2003 Standout
Cytotoxic T lymphocyte response against non-immunoselected tumor antigens predicts the outcome of gene therapy with IL-12-transduced tumor cell vaccine
1999
Immunotherapy for peritoneal ovarian carcinoma metastasis using ex vivo expanded tumor infiltrating lymphocytes
1996
Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards
2016 Standout
The Effect of Infections on Susceptibility to Autoimmune and Allergic Diseases
2002 Standout
Expression and modulation of major histocompatibility antigens on murine primary brain tumor in vitro
1991
Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer
2003 Standout
Activation of the MAPK pathway is a common event in uveal melanomas although it rarely occurs through mutation of BRAF or RAS
2005
Granulocyte-Macrophage Colony-Stimulating Factor Gene-Modified Autologous Tumor Vaccines in Non-Small-Cell Lung Cancer
2004
Identification of genes involved in epithelial-mesenchymal transition and tumor progression
2001
Imaging in the era of molecular oncology
2008 StandoutNature
Cancer immunotherapy: breaking the barriers to harvest the crop
2004 StandoutNobel
Renal-Cell Carcinoma
1996 Standout
Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up.
1993
Subcutaneous interleukin-2 plus interferon alfa-2a in metastatic renal cancer: an outpatient multicenter trial.
1993
Recombinant interferon alfa-2a with or without vinblastine in metastatic renal cell carcinoma: Results of a European multi-center phase III study
1992
Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
2007 Standout
Phase I Trial of Large Multivalent Immunogen Derived from Melanoma Lysates in Patients with Disseminated Melanoma
2004
eggNOG 4.5: a hierarchical orthology framework with improved functional annotations for eukaryotic, prokaryotic and viral sequences
2015 Standout
T-cell help for cytotoxic T lymphocytes is mediated by CD40–CD40L interactions
1998 StandoutNature
Induction of Immune Responses in Patients with B-Cell Lymphoma against the Surface-Immunoglobulin Idiotype Expressed by Their Tumors
1992
Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells
1999 StandoutNobel
Recombinant Interferon‐alpha with or without Vinblastine in Metastatic Renal Carcinoma Results of a Randomised Phase II Study
1989
Epithelial–mesenchymal transitions in tumour progression
2002 Standout
Cancer immunotherapy: moving beyond current vaccines
2004 Standout
Trastuzumab — Mechanism of Action and Use in Clinical Practice
2007 Standout
Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi
2008 StandoutNature
RNA as a tumor vaccine: a review of the literature
2001
Relationship Between Disease-Free Interval and Survival in Patients With Recurrent Melanoma
1992
Differentiation of Phagocytic Monocytes into Lymph Node Dendritic Cells In Vivo
1999 StandoutNobel
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
2017 Standout
T Cell Surveillance of Oncogene-Induced Prostate Cancer Is Impeded by T Cell-Derived TGF-β1 Cytokine
2011 StandoutNobel
Cancer immunotherapy comes of age
2011 StandoutNature
Activation-Induced Cytidine Deaminase Expression in CD4+ T Cells is Associated with a Unique IL-10-Producing Subset that Increases with Age
2011 StandoutNobel
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
2002 Standout
Mature dendritic cells boost functionally superior CD8+ T-cell in humans without foreign helper epitopes
2000 StandoutNobel
Neuroblastoma
2007 Standout
Clinical Pharmacokinetics of Interferons
1990
Angiogenesis in cancer, vascular, rheumatoid and other disease
1995 Standout
β-Arrestin and Mdm2 Mediate IGF-1 Receptor-stimulated ERK Activation and Cell Cycle Progression
2007 StandoutNobel
Regulation of Thymidylate Synthase in Human Colon Cancer Cells Treated with 5-Fluorouracil and Interferon-Gamma
1993
Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting
2012 StandoutNatureNobel
5-Fluorouracil: mechanisms of action and clinical strategies
2003 Standout
Extracellular mRNA Induces Dendritic Cell Activation by Stimulating Tumor Necrosis Factor-α Secretion and Signaling through a Nucleotide Receptor
2002 StandoutNobel
In Vivo Analysis of Aicda Gene Regulation: A Critical Balance between Upstream Enhancers and Intronic Silencers Governs Appropriate Expression
2013 StandoutNobel
History of myeloid-derived suppressor cells
2013
Adjuvant therapy for high‐risk primary and resected metastatic melanoma
2003
Microenvironmental regulation of tumor progression and metastasis
2013 Standout
Fully mobilizing host defense: Building better vaccines
1998
Phase I/II study of treatment with dendritic cell vaccines in patients with disseminated melanoma
2004
Advances in targeted therapies for hepatocellular carcinoma in the genomic era
2015
Mutations in GNA11 in Uveal Melanoma
2010 Standout
Bacterial agents protect against autoimmune disease. I. Mice pre-exposed to Bordetella pertussis or Mycobacterium tuberculosis are highly refractory to induction of experimental autoimmune encephalomyelitis
1992
Local and Systemic Effects of Intradermal Recombinant Interferon-γ in Patients with Lepromatous Leprosy
1986 StandoutNobel
Administration of recombinant interferon gamma to cancer patients enhances monocyte secretion of hydrogen peroxide.
1985
Subcutaneous vaccination with irradiated, cytokine-producing tumor cells stimulates CD8+ cell-mediated immunity against tumors located in the "immunologically privileged" central nervous system.
1996
The insulin-like growth factor-I receptor inhibitor picropodophyllin causes tumor regression and attenuates mechanisms involved in invasion of uveal melanoma cells.
2006
Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages
2015
Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected
2015
Idiotypic vaccination against human B-cell lymphoma. Rescue of variable region gene sequences from biopsy material for assembly as single-chain Fv personal vaccines
1994 StandoutNobel
Role of Cytokine Therapy in 2006 and Beyond for Metastatic Renal Cell Cancer
2006
Integrated NY-ESO-1 antibody and CD8+T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab
2011 StandoutNobel
Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection
2002 Standout
Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma
2008 StandoutNobel
The TLR-7 Agonist, Imiquimod, Enhances Dendritic Cell Survival and Promotes Tumor Antigen-Specific T Cell Priming: Relation to Central Nervous System Antitumor Immunity
2006
Protective antitumor immunity induced by immunization with completely allogeneic tumor cells.
1996
Synergism of Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade and Depletion of Cd25+ Regulatory T Cells in Antitumor Therapy Reveals Alternative Pathways for Suppression of Autoreactive Cytotoxic T Lymphocyte Responses
2001 StandoutNobel
Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients
2008 StandoutNobel
APOBEC3G Generates Nonsense Mutations in Human T-Cell Leukemia Virus Type 1 Proviral Genomes In Vivo
2010
Orthologous Gene Clusters and Taxon Signature Genes for Viruses of Prokaryotes
2012
IMMUNOTHERAPY FOR METASTATIC RENAL CELL CARCINOMA
1993
Bone Marrow–generated Dendritic Cells Pulsed with Tumor Extracts or Tumor RNA Induce Antitumor Immunity against Central Nervous System Tumors
1997
Human melanoma cells do not express Fas (Apo-1/CD95) ligand.
1999
Immunobiology of Dendritic Cells
2000 Standout
The Chemistry of Neutron Capture Therapy
1998 Standout
HUMAN T CELL RESPONSES AGAINST MELANOMA
2005
Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+regulatory T cells, evoking antitumor immune responses in humans
2013 StandoutNobel
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
2018 Standout
Vaccination With Irradiated, Autologous Melanoma Cells Engineered to Secrete Granulocyte-Macrophage Colony-Stimulating Factor by Adenoviral-Mediated Gene Transfer Augments Antitumor Immunity in Patients With Metastatic Melanoma
2003
Boron neutron capture therapy for cancer. Realities and prospects
1992
Epithelial-mesenchymal transition and its implications for fibrosis
2003 Standout
Expression of hypoxia-inducible factor 1? in brain tumors
2000 StandoutNobel
Phase I Clinical Trial of the Immunocytokine EMD 273063 in Melanoma Patients
2004
Innate NKT lymphocytes confer superior adaptive immunity via tumor-capturing dendritic cells
2005 StandoutNobel
Prospective Randomized Trial of Interferon Alfa-2a Plus Vinblastine Versus Vinblastine Alone in Patients With Advanced Renal Cell Cancer
1999
Phase III Multicenter Randomized Trial of the Dartmouth Regimen Versus Dacarbazine in Patients With Metastatic Melanoma
1999
Works of M S Mitchell being referenced
The role of immunohistochemistry and fluorescence in situ hybridization for HER2/neu in assessing the prognosis of breast cancer.
1999
Active specific immunotherapy of melanoma
1995
Combining Chemotherapy With Biological Response Modifiers in Treatment of Cancer
1988
Active-specific immunotherapy for melanoma.
1990
Assignment of a Human Melanoma Associated Gene MG50 (D2S448) to Chromosome 2p25.3 by Fluorescence in Situ Hybridization
1994
Sequence analysis of bacteriophage T4 DNA packaging/terminase genes 16 and 17 reveals a common ATPase center in the large subunit of viral terminases
2002
Increased effectiveness of interferon alfa-2b following active specific immunotherapy for melanoma.
1994
Association of HLA phenotype with response to active specific immunotherapy of melanoma.
1992
Recombinant alfa interferon in renal cell carcinoma: a randomized trial of two routes of administration.
1987
Relapse in the central nervous system in melanoma patients successfully treated with biomodulators.
1989
Immunological effects of recombinant interferon-alpha 2 in cancer patients.
1983
Characterization of uveal melanoma cell lines that grow as xenografts in rabbit eyes.
1989
Systemic bacillus Calmette-Guérin (BCG) activates natural suppressor cells.
1978
Immunotherapy for Melanoma
1973
Protection against experimental cerebral metastases of murine melanoma B16 by active immunization.
1993
Phase II study of recombinant alpha interferon in the treatment of advanced non-small cell lung carcinoma.
1985
Phase I study of recombinant beta-interferon given by four-hour infusion.
1987
Phase III trial of melacine?? melanoma theraccine versus combination chemotherapy in the treatment of stage IV melanoma
1997
Increased lysis of melanoma by in vivo-elicited human lymphokine-activated killer cells after addition of antiganglioside antibodies in vitro.
1990
Phenotypic and Genotypic Comparisons of Human T-Cell Leukemia Virus Type 1 Reverse Transcriptases from Infected T-Cell Lines and Patient Samples
2007